Data / Drug companies / Potassium iodide
Potassium iodide: 10 companies and 20 products in the FDA NDC directory
Potassium iodide is listed in the FDA National Drug Code Directory by 10 companies, with 20 products in commercial distribution. 3 of the products (15.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are pellet; solution; tablet, and the newest product started marketing on August 18, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 10
- Products
- 20
- Generic (ANDA) products
- 3 (15.0%)
- Application numbers
- 3
- Routes
- Oral
- Brand names
- Kali Iodatum, Iosat, Sski, Kali Iodatum 1X, ThyroSafe, Thyrosafe
- openFDA record search
- api.fda.gov
Companies that list potassium iodide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Boiron | 9 | pellet | Unapproved homeopathic products | March 3, 1983 |
| Anbex Inc. | 2 | tablet | New drug applications (NDA) | May 1, 2013 |
| BTG International Inc. | 2 | tablet | Generic drugs (ANDA) | November 26, 2025 |
| Atlantic Biologicals Corp. | 1 | solution | Other unapproved drugs | November 13, 2017 |
| Avondale Pharmaceuticals, LLC | 1 | solution | Other unapproved drugs | November 13, 2017 |
| Bryant Ranch Prepack | 1 | solution | Other unapproved drugs | December 29, 2021 |
| Emerald Therapeutics, LLC | 1 | solution | Other unapproved drugs | August 18, 2026 |
| Mission Pharmacal Company | 1 | solution | Generic drugs (ANDA) | May 15, 2016 |
| Natural Creations, Inc | 1 | liquid | Unapproved homeopathic products | May 29, 2007 |
| Nivagen Pharmaceuticals, Inc. | 1 | solution | Other unapproved drugs | December 29, 2021 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Pellet | 9 | 45% |
| Solution | 6 | 30% |
| Tablet | 4 | 20% |
| Liquid | 1 | 5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Unapproved homeopathic products | 10 | 50% |
| Other unapproved drugs | 5 | 25% |
| Generic drugs (ANDA) | 3 | 15% |
| New drug applications (NDA) | 2 | 10% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.